Zynerba Pharmaceuticals Inc. (Nasdaq: ZYNE) reported positive results from a Phase 2 FAB-C clinical trial of ZYN002 cannabidiol gel in children with Fragile X syndrome sending the stock price soaring $3.25 to close at $9.44.
Positive trial results for Zynerba Pharmaceuticals
September 28, 2017 at 17:55 PM EDT
